Favorable Gleason 3+4 Prostate Cancer Shows Comparable Outcomes With Gleason 3+3 Prostate Cancer: Implications for the Expansion of Selection Criteria for Active Surveillance

被引:7
作者
Lee, Hakmin [1 ]
Lee, In Jae [1 ]
Byun, Seok-Soo [1 ,2 ]
Lee, Sang Eun [1 ]
Hong, Sung Kyu [1 ,2 ]
机构
[1] Seoul Natl Univ, Dept Urol, Bundang Hosp, Seongnam, South Korea
[2] Seoul Natl Univ, Dept Urol, Coll Med, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Active surveillance; Biopsy; Gleason score; Prostatectomy; Prostate cancer; ISUP CONSENSUS CONFERENCE; RADICAL PROSTATECTOMY; INTERNATIONAL-SOCIETY; NEEDLE-BIOPSY; FOLLOW-UP; PATTERN; LOW-RISK; INTERMEDIATE; COHORT; DISEASE;
D O I
10.1016/j.clgc.2017.07.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To investigate the feasibility of active surveillance (AS) in biopsy Gleason score (GS) 3 + 4 prostate cancer (PCa), we compared the outcomes of biopsy GS 3 + 3 and 3 + 4 PCa after radical prostatectomy. Patients and Methods: We analyzed the data of 1491 patients undergoing radical prostatectomy for biopsy GS 3 + 3 or 3 + 4 PCa who fulfilled the low-risk criteria of the National Comprehensive Cancer Network guidelines regardless of GS. The favorable GS 3 + 4 group was defined as having core involvement <= 50%, prostate-specific antigen density <= 0.2 ng/mL/cm3, and number of positive cores <= 2 (maximal 1 core of GS 3 + 4). Results: The GS 3 + 4 group showed significantly worse pathologic outcomes, including pathologic GS, pathologic stage, and seminal vesicle invasion rate (all P <.001), as well as worse biochemical recurrenceefree survival (P <.001) than the GS 3 + 3 group. However, the favorable GS 3 + 4 subgroup showed no significant differences in the pathologic outcomes (all P >.05) and in biochemical recurrenceefree survival (P = .817) compared to the GS 3 + 3 group. Conclusion: Despite the application of low-risk criteria, GS 3 + 4 PCa patients showed significantly worse outcomes than GS 3 + 3 patients. However, favorable GS 3 + 4 patients showed comparable clinicopathologic outcomes with GS 3 + 3 patients, suggesting possible expansion of AS for the favorable GS 3 + 4 group. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:E1117 / E1122
页数:6
相关论文
共 29 条
[21]  
National Comprehensive Cancer Network, 2017, CLIN PRACT GUID ONC
[22]   Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort [J].
Newcomb, Lisa F. ;
Thompson, Ian M., Jr. ;
Boyer, Hilary D. ;
Brooks, James D. ;
Carroll, Peter R. ;
Cooperberg, Matthew R. ;
Dash, Atreya ;
Ellis, William J. ;
Fazli, Ladan ;
Feng, Ziding ;
Gleave, Martin E. ;
Kunju, Priya ;
Lance, Raymond S. ;
McKenney, Jesse K. ;
Meng, Maxwell V. ;
Nicolas, Marlo M. ;
Sanda, Martin G. ;
Simko, Jeffry ;
So, Alan ;
Tretiakova, Maria S. ;
Troyer, Dean A. ;
True, Lawrence D. ;
Vakar-Lopez, Funda ;
Virgin, Jeff ;
Wagner, Andrew A. ;
Wei, John T. ;
Zheng, Yingye ;
Nelson, Peter S. ;
Lin, Daniel W. .
JOURNAL OF UROLOGY, 2016, 195 (02) :313-320
[23]  
Perlis N, 2017, J UROLOGY, V197, P75, DOI 10.1016/j.juro.2016.07.076
[24]   Risk Group and Death From Prostate Cancer Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer [J].
Raldow, Ann C. ;
Zhang, Danjie ;
Chen, Ming-Hui ;
Braccioforte, Michelle H. ;
Moran, Brian J. ;
D'Amico, Anthony V. .
JAMA ONCOLOGY, 2015, 1 (03) :334-340
[25]   Medium-term Outcomes of Active Surveillance for Localised Prostate Cancer [J].
Selvadurai, Elizabeth D. ;
Singhera, Mausam ;
Thomas, Karen ;
Mohammed, Kabir ;
Woode-Amissah, Ruth ;
Horwich, Alan ;
Huddart, Robert A. ;
Dearnaley, David P. ;
Parker, Chris C. .
EUROPEAN UROLOGY, 2013, 64 (06) :981-987
[26]   Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study [J].
Stattin, Par ;
Holmberg, Erik ;
Johansson, Jan-Erik ;
Holmberg, Lars ;
Adolfsson, Jan ;
Hugosson, Jonas .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (13) :950-958
[27]   Prostate Cancer-Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era [J].
Stephenson, Andrew J. ;
Kattan, Michael W. ;
Eastham, James A. ;
Bianco, Fernando J., Jr. ;
Yossepowitch, Ofer ;
Vickers, Andrew J. ;
Klein, Eric A. ;
Wood, David P. ;
Scardino, Peter T. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4300-4305
[28]   Feasibility for active surveillance in biopsy Gleason 3+4 prostate cancer: an Australian radical prostatectomy cohort [J].
Wong, Lih-Ming ;
Tang, Vincent ;
Peters, Justin ;
Costello, Anthony ;
Corcoran, Niall .
BJU INTERNATIONAL, 2016, 117 :82-87
[29]   Prostate Cancer Specific Mortality and Gleason 7 Disease Differences in Prostate Cancer Outcomes Between Cases With Gleason 4+3 and Gleason 3+4 Tumors in a Population Based Cohort [J].
Wright, Jonathan L. ;
Salinas, Claudia A. ;
Lin, Daniel W. ;
Kolb, Suzanne ;
Koopmeiners, Joseph ;
Feng, Ziding ;
Stanford, Janet L. .
JOURNAL OF UROLOGY, 2009, 182 (06) :2702-2707